UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 1213, 2021

IMMUNE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-36602	52-1841431
Nevada	001-36602	86-3202343
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1 Bridge Plaza North, Suite 270, Fort Lee, NJ		07024
2510 East Sunset Road Suite 5 – 889, Las Vegas, NV		89120
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (201) 464-2677

(Former name or former address, if changed since last report) ~~N/A~~

1 Bridge Plaza North, Suite 270, Fort Lee, NJ

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common stock		IMNPQ		OTC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

[ ]

Item 2.01.

Completion of acquisition or disposition of Assets

On April 12, 2021 a new Nevada corporation was formed to merge and survive the bankrupt Immune Pharmaceuticals Inc (NJ).

The new corporation retains the same name however is registered in the state of Nevada. The company further has updated its address.

The new corporation is not subject to chapter 7 bankruptcy and has no association with any legal issues relating to the previous corporation.

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On April 1213, 2021, ~~Adeel~~Devin ~~Ahmed-Daudpota~~J Shaw, age 34, has been appointed as the ~~President and Interim~~ Chief ~~Executive~~Finance Officer ~~of the Immune Pharmaceuticals to fill the vacancy that resulted from the company entering into chapter 7~~.

Mr. ~~Ahmed-Daudpota~~Shaw is an investment banker, predominantly specializing in ~~M&A,~~Collateral ~~restructurings~~trading, ~~and~~Equity ~~Special~~& ~~Situations.~~Debt Incapital ~~connection with~~market his appointment to the board of Immune Pharmaceuticals as Interim CEO, Mr Daudpota’s role Will entail providing the company’s shareholders options to continue trading and for identifying and merging with another viable pharmaceutical businesstransactions.

~~The~~In connection with his appointment asto ~~such~~the ~~carries~~board noof ~~compensation~~Immune ~~and~~Pharmaceuticals ~~does~~as ~~not~~CFO, ~~cover~~Mr ~~any~~Shaw’s ~~expenses.~~role ~~This~~Will isentail ~~subject~~planning toand ~~change~~implementing all ~~post-merger~~financial activities for the company.

The ~~proposed~~appointment ~~merger~~as issuch ~~intended~~carries tono ~~protect~~compensation ~~existing~~and ~~shareholder~~does ~~interest~~not ~~and~~cover ~~provide~~any aexpenses. ~~private~~This ~~pharmaceutical~~is ~~company~~subject ato ~~public~~change ~~company~~once ~~and large~~full ~~shareholder~~employment ~~base~~has been toagreed ~~raise~~with ~~additional~~the ~~capital~~company.

- 2 -

Item 8.01.

Other Events

MrThe ~~Daudpota~~company ~~effective~~is ~~immediately~~working ~~upon~~on ~~appointment~~documents ~~shall be responsible for updating the company’s filings~~ to bring ~~the company~~ up to date ~~with~~all ~~its~~SEC ~~regulatory requirements, In addition Mr~~filings. ~~Daudpota is responsible for providing a viable merger candidate and overseeing the merger with a new entity.~~

MrThe ~~Daudpota~~company ~~hereby~~is ~~notifies~~also ~~the~~working ~~market~~on ~~that~~full aemployment ~~merger~~contracts isfor ~~expected~~the interim CEO to ~~take~~make ~~place~~this ~~within~~a ~~the~~permanent ~~coming~~position ~~weeks~~and ~~that~~is ~~will~~further ~~ensure~~agreeing a contract with the ~~common~~new ~~stock holders~~CFO. The market will be ~~protected~~updated ~~from discontinuation~~ of ~~trading~~this orin ~~loss~~the ofcoming ~~public equity~~weeks.

MrThe ~~Daudpota~~new ~~has~~Nevada ~~secured~~corporation ~~the~~is ~~full support of United General LTD~~ a UKnew ~~investment~~entity ~~firm~~unrelated ~~and~~to ~~liquidity~~any ~~provider,~~events ~~Where~~surrounding hethe ~~also~~previous ~~he holds a board position~~bankruptcy.

The ~~proposed~~board ~~merger plan~~ will ~~separate~~be ~~the~~announcing ~~Immune~~a ~~Pharmaceuticals~~new ~~LLC~~pharmaceutical ~~(In~~asset ~~chapter~~once 7)details ~~into~~have ~~the~~been ~~surviving entity that will not be subject to chapter 7 bankruptcy~~finalized.

~~Holders~~We ofwill ~~common~~be ~~stock~~applying ~~under~~to ~~this~~Finra ~~structure~~once ~~will~~all ~~retain~~SEC afilings ~~shareholding~~are inup ~~the~~to ~~surviving~~date ~~public~~to ~~company~~have ~~and~~the ~~will~~“Q” bestatus ~~afforded~~removed, aswe ~~such~~expect ~~shareholder~~this corporate ~~rights~~action into ~~the~~be ~~new~~initiated ~~operating~~within ~~pharmaceutical~~30 ~~company post-merger~~days.

Upon completion of the merger, we will appoint a new board and apply to have the bankruptcy status lifted from Finra.

Exhibit Number		Description

Exhibit 1		Certificate of charter
Exhibit 2		Business license

- 3 2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	IMMUNE PHARMACEUTICALS INC.

	By:	/s/ Adeel Ahmed-Daudpota
	Name:	Adeel Ahmed-Daudpota
	Title:	President and Interim Chief Executive Officer

Date: April 1213, 2021

- 4 3-

Filing Compare · IMMUNE PHARMACEUTICALS INC